These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Mutation of the p53 tumor suppressor gene in spontaneously occurring osteosarcomas of the dog. Johnson AS; Couto CG; Weghorst CM Carcinogenesis; 1998 Jan; 19(1):213-7. PubMed ID: 9472714 [TBL] [Abstract][Full Text] [Related]
11. Novel application of single-cell next-generation sequencing for determination of intratumoral heterogeneity of canine osteosarcoma cell lines. Ayers J; Milner RJ; Cortés-Hinojosa G; Riva A; Bechtel S; Sahay B; Cascio M; Lejeune A; Shiomitsu K; Souza C; Hernandez O; Salute M J Vet Diagn Invest; 2021 Mar; 33(2):261-278. PubMed ID: 33446089 [TBL] [Abstract][Full Text] [Related]
12. Biology, diagnosis and treatment of canine appendicular osteosarcoma: similarities and differences with human osteosarcoma. Morello E; Martano M; Buracco P Vet J; 2011 Sep; 189(3):268-77. PubMed ID: 20889358 [TBL] [Abstract][Full Text] [Related]
13. Enrofloxacin enhances the effects of chemotherapy in canine osteosarcoma cells with mutant and wild-type p53. York D; Withers SS; Watson KD; Seo KW; Rebhun RB Vet Comp Oncol; 2017 Sep; 15(3):1087-1100. PubMed ID: 27333821 [TBL] [Abstract][Full Text] [Related]
14. Recent and current clinical trials in canine appendicular osteosarcoma. Poon AC; Matsuyama A; Mutsaers AJ Can Vet J; 2020 Mar; 61(3):301-308. PubMed ID: 32165755 [TBL] [Abstract][Full Text] [Related]
15. Sakthikumar S; Elvers I; Kim J; Arendt ML; Thomas R; Turner-Maier J; Swofford R; Johnson J; Schumacher SE; Alföldi J; Axelsson E; Couto CG; Kisseberth WC; Pettersson ME; Getz G; Meadows JRS; Modiano JF; Breen M; Kierczak M; Forsberg-Nilsson K; Marinescu VD; Lindblad-Toh K Cancer Res; 2018 Jul; 78(13):3421-3431. PubMed ID: 29724721 [TBL] [Abstract][Full Text] [Related]
16. Analysis of gene expression of prostaglandin EP4 receptor in canine osteosarcoma. Musser ML; Viall AK; Phillips RL; Hostetter JM; Johannes CM Can J Vet Res; 2021 Jan; 85(1):68-71. PubMed ID: 33390656 [TBL] [Abstract][Full Text] [Related]
18. Immune pathways and TP53 missense mutations are associated with longer survival in canine osteosarcoma. Das S; Idate R; Regan DP; Fowles JS; Lana SE; Thamm DH; Gustafson DL; Duval DL Commun Biol; 2021 Oct; 4(1):1178. PubMed ID: 34635775 [TBL] [Abstract][Full Text] [Related]
19. Inactivation of p53 and retinoblastoma family pathways in canine osteosarcoma cell lines. Levine RA; Fleischli MA Vet Pathol; 2000 Jan; 37(1):54-61. PubMed ID: 10643981 [TBL] [Abstract][Full Text] [Related]
20. Update on the biology and management of canine osteosarcoma. Chun R; de Lorimier LP Vet Clin North Am Small Anim Pract; 2003 May; 33(3):491-516, vi. PubMed ID: 12852233 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]